Cereno Scientific has announced that a collaboration agreement has been entered with Abbott regarding use of its CardioMEMS HF System in the upcoming Phase II study with Cereno’s drug candidate CS1.
The technology will be used to remotely and continously monitor the pulmonary pressure in the Ph